Medtronic plc (MDT) Analysts See $1.38 EPS on May, 24

May 16, 2018 - By Kristin Houston

Medtronic plc (NYSE:MDT) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.02. That’s change of 0.10, from 2017Q3’s 1.12. 65 investors sold all, 427 reduced holdings as Medtronic plc ratio dived. 393 grew stakes while 111 funds acquired stakes. Funds hold 1.04 billion shares thus 2.98% less from 2017Q3’s 1.07 billion shares.
Cim Limited Liability Corporation invested 0.09% of its capital in Medtronic plc (NYSE:MDT). Old Second Retail Bank Of Aurora has invested 0.04% in Medtronic plc (NYSE:MDT). Silchester Ltd Liability Partnership holds 22,278 shs or 0.08% of its capital. Chemung Canal Company accumulated 13,447 shs or 0.24% of the stock. Sector Pension Board has invested 0.04% in Medtronic plc (NYSE:MDT). Essex Fin Services stated it has 19,516 shs or 0.37% of all its holdings. Rafferty Asset Ltd Liability Corporation holds 30,153 shs or 0.04% of its capital. Stack owns 167,441 shs for 1.36% of their capital. Grandfield Dodd Limited Liability Corp holds 1.8% in Medtronic plc (NYSE:MDT) or 209,008 shs. Stifel Financial has invested 0.3% in Medtronic plc (NYSE:MDT). 13,380 are owned by Dynamic Capital Mgmt Ltd. Comerica Inc accumulated 11,664 shs. The Pennsylvania-based Hbk Sorce Advisory Limited Liability Company has invested 0.05% in Medtronic plc (NYSE:MDT). Hardman Johnston Advisors Ltd reported 324,707 shs or 1.11% of all its holdings. New York-based Canandaigua Bank & Trust And Trust has invested 0.29% in Medtronic plc (NYSE:MDT).

Medtronic plc (NYSE:MDT) is expected to report earnings on May, 24 before the open., as reported by RTT. The earnings per share diference is $0.05 or 3.76 % up from last years number. Previous year: $1.33; Analysts forcast: $1.38. The profit will be $1.87 billion for MDT if $1.38 earnings per share becomes true. After $1.17 earnings per share was reported last quarter, analysts now see EPS growth of 17.95 % for Medtronic plc. Ticker’s shares touched $85.54 during the last trading session after 1.39% change.Medtronic plc has volume of 3.49 million shares. Since May 16, 2017 MDT has declined 3.54% and is downtrending. The stock underperformed the S&P 500 by 15.09%.

Medtronic plc (NYSE:MDT) Ratings Coverage

In total 11 analysts cover Medtronic (NYSE:MDT). “Buy” rating has 9, “Sell” are 0, while 2 are “Hold”. (NYSE:MDT) has 82% bullish analysts. 13 are the (NYSE:MDT)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Needham with “Buy” on Tuesday, November 21. On Wednesday, February 21 the stock has “Buy” rating by Needham. In Friday, April 27 report Piper Jaffray initiated it with “Buy” rating and $9000 target. On Tuesday, December 12 the rating was upgraded by Argus Research to “Buy”. The stock rating was maintained by Morgan Stanley with “Equal-Weight” on Monday, February 5. The stock rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, March 29. In Wednesday, November 22 report Stifel Nicolaus maintained the stock with “Hold” rating. On Tuesday, December 12 the stock of Medtronic plc (NYSE:MDT) earned “Buy” rating by BMO Capital Markets. On Thursday, February 22 the firm earned “Buy” rating by Citigroup. On Tuesday, January 2 Bank of America upgraded the shares of MDT in report to “Buy” rating.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide.The firm is valued at $115.94 billion. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software.The P/E ratio is 41.85. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

For more Medtronic plc (NYSE:MDT) news posted briefly go to: Investingnews.com, Globenewswire.com, Streetinsider.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “Medtronic Begins US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with …” posted on May 16, 2018, “Mike Weinstein to Join Medtronic as Senior Vice President of Strategy” on May 07, 2018, “Medtronic (MDT) Highlights New Analysis Showing Cardiac Resynchronization Therapy Feature Associated with …” with a publish date: May 15, 2018, “Medtronic Should Focus On Aggressive Deleveraging” and the last “Medtronic (MDT) Launches US Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients …” with publication date: May 16, 2018.

Medtronic plc (NYSE:MDT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.